AIRLINK 62.48 Increased By ▲ 2.05 (3.39%)
BOP 5.36 Increased By ▲ 0.01 (0.19%)
CNERGY 4.58 Decreased By ▼ -0.02 (-0.43%)
DFML 15.50 Increased By ▲ 0.66 (4.45%)
DGKC 66.40 Increased By ▲ 1.60 (2.47%)
FCCL 17.59 Increased By ▲ 0.73 (4.33%)
FFBL 27.70 Increased By ▲ 2.95 (11.92%)
FFL 9.27 Increased By ▲ 0.21 (2.32%)
GGL 10.06 Increased By ▲ 0.10 (1%)
HBL 105.70 Increased By ▲ 1.49 (1.43%)
HUBC 122.30 Increased By ▲ 4.78 (4.07%)
HUMNL 6.60 Increased By ▲ 0.06 (0.92%)
KEL 4.50 Decreased By ▼ -0.05 (-1.1%)
KOSM 4.48 Decreased By ▼ -0.09 (-1.97%)
MLCF 36.20 Increased By ▲ 0.79 (2.23%)
OGDC 122.92 Increased By ▲ 0.53 (0.43%)
PAEL 23.00 Increased By ▲ 1.09 (4.97%)
PIAA 29.34 Increased By ▲ 2.05 (7.51%)
PIBTL 5.80 Decreased By ▼ -0.14 (-2.36%)
PPL 107.50 Increased By ▲ 0.13 (0.12%)
PRL 27.25 Increased By ▲ 0.74 (2.79%)
PTC 18.07 Increased By ▲ 1.97 (12.24%)
SEARL 53.00 Decreased By ▼ -0.63 (-1.17%)
SNGP 63.21 Increased By ▲ 2.01 (3.28%)
SSGC 10.80 Increased By ▲ 0.05 (0.47%)
TELE 9.20 Increased By ▲ 0.71 (8.36%)
TPLP 11.44 Increased By ▲ 0.86 (8.13%)
TRG 70.86 Increased By ▲ 0.95 (1.36%)
UNITY 23.62 Increased By ▲ 0.11 (0.47%)
WTL 1.28 No Change ▼ 0.00 (0%)
BR100 6,944 Increased By 65.8 (0.96%)
BR30 22,827 Increased By 258.6 (1.15%)
KSE100 67,142 Increased By 594.3 (0.89%)
KSE30 22,090 Increased By 175.1 (0.8%)
Pakistan

Pakistan evaluating China’s clinical trials proposal, informs Mirza

“Too early to say anything!” added Mirza indicating that the decision might take some time. China’s pharmaceut
Published April 24, 2020
  • “Too early to say anything!” added Mirza indicating that the decision might take some time.
  • China’s pharmaceutical company Sinopharm, claimed to have developed a vaccine for the coronavirus and has invited Pakistan’s National Institute of Health for clinical trials.

Pakistan is currently evaluating a Chinese pharmaceutical company offer to conduct clinical trials of inactivated novel coronavirus (COVID-19) vaccines in the country, informed Special Assistant for Health, Zafar Mirza on Friday.

“About vaccine for COVID-19: Pakistan is approached by a Chinese company for possible trails. We have asked for more information, which we will evaluate through relevant experts from safety, ethics, regulation and feasibility perspectives before deciding,” said Zafar Mirza, at his Twitter handle.

“Too early to say anything!” added Mirza indicating that the decision might take some time. The statement comes after China’s pharmaceutical company Sinopharm, claimed to have developed vaccine for the coronavirus and has invited Pakistan’s National Institute of Health for clinical trials.

“Through our representative HealthBee Projects Private Limited, we would like to extend our offer for cooperation on conducting clinical trials of our recently developed inactivated COVID-19 vaccine to the National Institute of Health (NIH) in our brotherly country, Pakistan,” read the letter sent to Major General Prof Dr. Aamir Ikram, Executive Director of National Institute of Health, by the general manager of China Sinopharm International Corp., Li Can.

“We hope that a successful clinical trial in Pakistan will make it one of the first few countries for the launch of a COVID-19 vaccine. The is the mission that Sinopharm has been given by the government," read the letter.

Talking to local media, Dr. Ikram informed that the public would get the good news within three months if it all goes well, and was hopeful that they would cover all the testing processes in three months period.

 

Comments

Comments are closed.